Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 10/20 | 0.65 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.44 |
| ▸ | RPA1 | P27694 | 1/20 | 0.43 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117654 | 0.86 | MARS1 (0.84) | MARS1L3MBTL1MALT1MEN1KMT2A | |
| SCHEMBL118666 | 0.79 | MARS1 (1.00) | MARS1PPP1CAL3MBTL1SMN1; SMN2RPA1 | |
| SCHEMBL8475502 | 0.72 | MALT1 (0.68) | MARS1PPP1CAMALT1SMN1; SMN2CHRNA7 | |
| SCHEMBL11759367 | 0.71 | KMT2A (0.53) | L3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL18353660 | 0.68 | MARS1 (0.59) | MARS1PPP1CAL3MBTL1MEN1KMT2A | |
| SCHEMBL27668785 | 0.68 | MARS1 (0.67) | MARS1PPP1CAL3MBTL1MEN1KMT2A | |
| SCHEMBL16982975 | 0.68 | CYP2A6 (0.51) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL116301 | 0.67 | MARS1 (1.00) | MARS1PPP1CAL3MBTL1SMN1; SMN2RPA1 | |
| SCHEMBL5521086 | 0.67 | KMT2A (0.55) | MARS1MEN1KMT2ACHRNA7RPA1 | |
| SCHEMBL14995357 | 0.66 | MARS1 (0.64) | MARS1PPP1CAL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | MARS1 55/4885PPP1CA 2582/4885L3MBTL1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.